Imagine discovering that you carry an inherited trait that significantly increases your risk of heart attack and stroke, yet most people have never heard of it and there’s currently no medication specifically designed to treat it. This describes the reality of elevated lipoprotein(a), commonly abbreviated as Lp(a), a genetic risk factor that affects approximately one in five people worldwide.
What Is Lp(a)?
Lipoprotein(a) is a type of cholesterol particle that circulates in your blood. Think of it as LDL cholesterol’s more dangerous cousin: it contains the same harmful cholesterol core but comes wrapped with an additional sticky protein called apolipoprotein(a). This extra component makes Lp(a) particularly troublesome because it not only contributes to plaque buildup in your arteries like regular cholesterol, but it also promotes inflammation and blood clotting.
Your Lp(a) level is determined almost entirely by your genetics. Unlike other cholesterol markers that respond to diet and exercise, the amount of Lp(a) in your blood remains relatively constant throughout your life, regardless of how healthy your lifestyle might be. If you inherited genes for high Lp(a) from one or both parents, you’ll carry this elevated risk from birth through old age.
The Cardiovascular Threat: Why Lp(a) Is So Dangerous
Elevated Lp(a) acts as a triple threat to cardiovascular health, which explains why it’s more dangerous than LDL cholesterol alone. First, it promotes atherosclerosis through accelerated plaque buildup in arteries. Second, it drives vascular inflammation and calcification that makes these plaques unstable and dangerous. Third, it increases thrombosis, or blood clotting risk, making heart attacks and strokes more likely to occur.
The unique structure of Lp(a) makes it particularly harmful through several interconnected mechanisms. When Lp(a) infiltrates the arterial wall, it deposits not just cholesterol but also oxidized phospholipids, which are potent inflammatory molecules. These oxidized lipids trigger dysfunction in the cells lining your blood vessels and attract immune cells, accelerating plaque growth. Compared to regular LDL cholesterol, Lp(a) particles are more adhesive and pro-inflammatory, creating plaques that are inherently less stable and more prone to rupture.
The inflammatory component of Lp(a) creates a cascade of problems. The apolipoprotein(a) portion carries these oxidized phospholipids, which activate immune pathways and lead to the release of inflammatory signals throughout the vascular system. This chronic inflammation doesn’t just make existing plaques grow faster; it makes them more vulnerable to sudden rupture, which is the primary trigger for heart attacks and strokes.
Perhaps most concerning is Lp(a)’s effect on calcification. The particle stimulates bone-forming signals in the smooth muscle cells of blood vessels, leading to progressive hardening of both arteries and heart valves. This explains why elevated Lp(a) is a major cause of aortic valve stenosis, independent of other cholesterol levels. Patients with high Lp(a) often develop this valve narrowing decades earlier than would be expected based on their other risk factors.
The clotting risk from Lp(a) adds another layer of danger. The apolipoprotein(a) component structurally mimics plasminogen, a key protein your body uses to break down blood clots. By competing with plasminogen, Lp(a) impairs your body’s natural ability to dissolve clots, creating what physicians call a pro-thrombotic state. This means that when a plaque does rupture, the resulting clot is more likely to completely block the artery, causing a full-blown heart attack or stroke rather than a minor event.
Research has consistently shown that people with elevated Lp(a) face a substantially higher risk of cardiovascular disease. Those with levels above 50 mg/dL (or 125 nmol/L, depending on the measurement system used) have approximately double the risk of heart attack compared to those with normal levels. This risk becomes even more pronounced when combined with other cardiovascular risk factors, as Lp(a) amplifies the danger from conditions like high blood pressure or diabetes.
Perhaps most concerning is that elevated Lp(a) can cause cardiovascular disease even in people who otherwise appear healthy. Young adults with normal blood pressure, healthy weight, and excellent cholesterol levels can still experience heart attacks if they have significantly elevated Lp(a). This is because Lp(a) doesn’t just raise cholesterol levels; it fundamentally changes how atherosclerosis develops, making it more aggressive and unpredictable.
Who Should Get Tested?
Given that Lp(a) levels remain stable throughout life, a single test can provide valuable information about your lifetime cardiovascular risk. Medical professionals increasingly recommend testing in several situations.
First, anyone with a personal history of premature cardiovascular disease (before age 55 in men or 65 in women) should be tested, as elevated Lp(a) may explain why they developed heart disease at a younger age than expected. Similarly, those with a strong family history of early heart disease or stroke should consider testing, since Lp(a) elevation runs in families.
Testing also makes sense for individuals with high cholesterol that doesn’t respond well to standard treatments, those with progressive cardiovascular disease despite optimal management of other risk factors, and anyone with aortic valve disease. Some experts argue that everyone should be tested at least once in their lifetime, given that approximately 20% of the population has elevated levels and the test only needs to be performed once.
The Current Treatment Landscape
Here’s where the situation becomes challenging: despite decades of research, there are currently no FDA-approved medications specifically designed to lower Lp(a). Traditional cholesterol-lowering drugs like statins have little to no effect on Lp(a) levels, and in some cases may even slightly increase them. While several promising therapies are in late-stage clinical trials, including RNA-based medications that can dramatically reduce Lp(a) levels, these treatments remain several years away from general availability.
This therapeutic gap means that people with elevated Lp(a) must take a different approach to managing their cardiovascular risk. Since the Lp(a) itself cannot currently be lowered through medication or lifestyle changes, the strategy shifts to aggressively managing every other modifiable risk factor. This approach becomes even more critical given Lp(a)’s multiple mechanisms of harm: since you cannot neutralize the inflammatory, thrombotic, and calcifying effects of Lp(a) directly, you must work harder to protect your cardiovascular system through other means.
Taking Control Through Risk Factor Management
The key principle for managing elevated Lp(a) is risk offset: if you cannot eliminate one risk factor, you must work harder to minimize all others. This comprehensive approach can significantly reduce overall cardiovascular risk despite the persistent elevation of Lp(a). Understanding that Lp(a) creates a pro-inflammatory and pro-thrombotic state makes this aggressive management approach even more logical and necessary.
Lipid management becomes paramount for those with high Lp(a). Working with healthcare providers to achieve the lowest possible LDL cholesterol levels, often below 70 mg/dL or even lower in high-risk individuals, helps counteract the additional cholesterol burden from Lp(a). This typically requires a combination of dietary changes and medications, with more aggressive targets than would be recommended for someone without elevated Lp(a). Since Lp(a) makes plaques more unstable, having less LDL cholesterol available for plaque formation becomes critically important.
Blood pressure control takes on heightened importance as well. Maintaining blood pressure below 130/80 mmHg through sodium restriction, following dietary approaches like the DASH or Mediterranean diet, regular exercise, and medication when necessary helps protect blood vessels already under stress from elevated Lp(a). Lower blood pressure reduces the mechanical stress on arterial walls where Lp(a)-laden plaques are developing, potentially slowing their progression and reducing rupture risk.
For those with diabetes or prediabetes, meticulous glucose control becomes essential. Keeping hemoglobin A1c below 7% and managing insulin resistance through weight management and physical activity helps prevent the synergistic damage that occurs when high blood sugar combines with elevated Lp(a). High glucose levels increase oxidative stress and inflammation, which can amplify the inflammatory effects of Lp(a)’s oxidized phospholipids.
Lifestyle modifications, while unable to lower Lp(a) directly, profoundly impact overall cardiovascular risk. Complete smoking cessation is non-negotiable, as tobacco use multiplies the already elevated risk from Lp(a) by further promoting inflammation and thrombosis. Regular physical activity, aiming for at least 150 minutes of moderate aerobic exercise weekly plus strength training, improves multiple risk factors simultaneously. Maintaining a healthy weight and following an anti-inflammatory Mediterranean-style diet rich in vegetables, fruits, whole grains, lean proteins, and healthy fats provides additional protection against the inflammatory cascade triggered by Lp(a).
Managing inflammation and clotting tendency becomes particularly relevant given Lp(a)’s pro-inflammatory and pro-thrombotic properties. Some individuals may benefit from low-dose aspirin therapy, though this requires careful discussion with healthcare providers to weigh benefits against bleeding risks. The anti-platelet effects of aspirin may partially counteract Lp(a)’s impairment of natural clot breakdown. Treating conditions like sleep apnea, managing stress through mindfulness or counseling, and prioritizing quality sleep all help reduce systemic inflammation that could synergize with Lp(a)’s inflammatory effects.
Healthcare providers may also discuss emerging strategies with appropriate patients. Some evidence suggests that low-dose PDE5 inhibitors, medications typically used for erectile dysfunction, may improve endothelial function and reduce cardiovascular events, potentially helping to counteract some of the vascular dysfunction caused by Lp(a), though this approach remains experimental and requires careful medical supervision.
Looking Forward
While the current inability to directly treat elevated Lp(a) feels frustrating, there’s reason for optimism. Multiple pharmaceutical companies are developing targeted therapies that show remarkable ability to lower Lp(a) levels in clinical trials. These medications, likely to become available within the next few years, will finally provide a direct treatment option that could neutralize Lp(a)’s triple threat of atherosclerosis, inflammation, and thrombosis.
Until then, the message for those with elevated Lp(a) is clear: knowledge is power. Understanding your Lp(a) status allows you to work with healthcare providers to implement a comprehensive risk reduction strategy. By aggressively managing all modifiable cardiovascular risk factors, many people with elevated Lp(a) can achieve overall cardiovascular risk levels similar to or even lower than those with normal Lp(a) but poorly controlled risk factors.
The discovery of elevated Lp(a) should serve not as a cause for despair but as motivation for proactive health management. While you cannot change your genetics, you can control numerous factors that determine whether those genetics translate into actual cardiovascular disease. Through comprehensive risk factor modification and vigilant medical care, the increased risk from elevated Lp(a) can be substantially mitigated while we await the arrival of targeted therapies.
References
- Andersson DP, Landucci L, Lagerros YT, Grotta A, Bellocco R, Lehtihet M, Holzmann MJ. Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease. J Am Coll Cardiol. 2021 Mar 30;77(12):1535-1550.
- Arsenault BJ, Loganath K, Girard A, Botezatu S, Zheng KH, Tzolos E, Abdoun K, Tastet L, Capoulade R, Côté N, Pibarot P, Dweck MR, Thanassoulis G. Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis. J Am Heart Assoc. 2025 Jan 7;14(1):e038955.
- Capoulade R, Yeang C, Chan KL, Pibarot P, Tsimikas S. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 Dec 1;3(12):1212-1217.
- Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Fitó M, Gea A, Hernán MA, Martínez-González MA; PREDIMED Study Investigators. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018 Jun 21;378(25):e34.
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-e1143.
- Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun;18(3):e308-e323.
- Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 Oct 14;43(39):3925-3946.
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188.
- Martínez-González MA, Gea A, Ruiz-Canela M. The Mediterranean Diet and Cardiovascular Health. Circ Res. 2019 Mar 1;124(5):779-798.
- Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, Michael LF, Ruotolo G, Gribble G, Navar AM, Nicholls SJ. Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial. JAMA. 2023 Dec 12;330(22):2161-2169.
- Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, Wolski K, Michael L, Haupt A, Krege JH; for the ALPACA Trial Investigators. Lepodisiran—A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). N Engl J Med. 2025 Jan 9;392(2):123-135.
- Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016 Nov;57(11):1953-1975.
- O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Češka R, Ezhov MV, Jukema JW, Jensen HK, Tokgözoğlu SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019 Mar 19;139(12):1483-1492.
- O’Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; for the OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022 Nov 17;387(20):1855-1864.
- O’Donoghue ML, Rosenson RS, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Murphy SA, Wang H, Wu Y, Shah T, Wang J, Wilmanski T, Sohn W, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results. J Am Coll Cardiol. 2024 Sep 3;84(9):790-797.
- Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60.
- Ruscica M, Greco MF, Ferri N, Corsini A. Lipoprotein(a) and PCSK9 inhibition: clinical evidence. Eur Heart J Suppl. 2020 Nov;22(Suppl L):L53-L56.
- Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Steg PG; ODYSSEY Outcomes Committees and Investigators. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433.
- Sebastian SA, Padda I, Johal G. Long-term impact of mediterranean diet on cardiovascular disease prevention: A systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2024 May;49(5):102509.
- Soulaidopoulos S, Terentes-Printzios D, Ioakeimidis N, Tsioufis KP, Vlachopoulos C. Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2024 Aug 14;10(5):403-412.
- Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. Lp(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:135-157.
- Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O’Dea L, Witztum JL; for the AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020 Jan 16;382(3):244-255.
- Tsimikas S, Moriarty PM, Stroes ESG. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. J Am Coll Cardiol. 2021 Mar 30;77(12):1576-1589.
